Webinar: Multiplex assays of the anti-apoptotic BCL-2 family

Last updated: 03rd February, 2022

Products are for professional/laboratory use only.

Multiplex assays of the anti-apoptotic BCL-2 family

A hallmark of cancer cells is defects in the apoptotic cell death program. Apoptosis is a highly regulated cell suicide process that functions to remove unwanted cells. One means of inhibiting the apoptotic pathway in cancer cells is through up-regulation of the anti-apoptotic BCL-2 family members, including BCL-2, BCL-XL and MCL-1. To restore the ability of cells to undergo apoptosis, small molecules have been designed to inhibit these proteins. However, a major question for using these small molecules is to predict which patients would respond.

To answer this question, the expression of multiple components of the BCL-2 family proteins was measured simultaneously in a multiplex format and correlated to response across panels of cell lines. This multiplex assay allows for accurate quantitation of protein levels. It is highly sensitive with wide dynamic range. This assay could also be used for studying drug response and is suitable for use in a high-throughput manner.


Watch webinar recording


During this webinar you will:

  • Hear about recent research on apoptosis in cancer drug development
  • Gain insight into how to successfully integrate multiplexed immunoassays into your cancer research workflow
  • Learn about best practices for running multiplex protein detection assays to generate the highest quality data

Request a Quote

Request Quote

Go BackGo Back